MDS_PHYTS
ID MDS_PHYTS Reviewed; 67 AA.
AC A0A1M4BLT1;
DT 17-JUN-2020, integrated into UniProtKB/Swiss-Prot.
DT 15-MAR-2017, sequence version 1.
DT 25-MAY-2022, entry version 13.
DE RecName: Full=Medusin-PT {ECO:0000303|PubMed:28469603, ECO:0000312|EMBL:SBO46661.1};
DE Flags: Precursor;
OS Phyllomedusa tarsius (Brownbelly leaf frog) (Phyllomedusa tarsia).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Amphibia;
OC Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae; Phyllomedusinae;
OC Phyllomedusa.
OX NCBI_TaxID=306084;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 49-66, FUNCTION, SYNTHESIS
RP OF 49-66, AMIDATION AT LEU-66, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP PRO-54 AND THR-58.
RC TISSUE=Skin secretion;
RX PubMed=28469603; DOI=10.3389/fmicb.2017.00628;
RA Gao Y., Wu D., Wang L., Lin C., Ma C., Xi X., Zhou M., Duan J.,
RA Bininda-Emonds O.R.P., Chen T., Shaw C.;
RT "Targeted modification of a novel amphibian antimicrobial peptide from
RT Phyllomedusa tarsius to enhance its activity against MRSA and microbial
RT biofilm.";
RL Front. Microbiol. 8:628-628(2017).
CC -!- FUNCTION: Antimicrobial peptide with activity against Gram-positive
CC bacteria S.epidermidis ATCC 12228 (MIC=50 uM) and S.aureus (MIC=64
CC ug/ml and MBC=128 ug/ml) (PubMed:28469603) (By similarity). Not active
CC against some Gram-positive bacteria (methicillin-resistant S.aureus
CC (MRSA), E.faecalis), Gram-negative bacterium E.coli ATCC 25922 and
CC fungus C.albicans at concentrations up to 100 uM (PubMed:28469603) (By
CC similarity). Can only slightly inhibit the formation of biofilm by
CC S.aureus (minimal biofilm inhibitionconcentration MBIC=512 ug/ml,
CC minimal biofilm eradication concentration MBEC>512 ug/ml)
CC (PubMed:28469603). Has an anti-inflammatory effect, since it inhibits
CC the production of the pro-inflammatory cytokines TNF-alpha and IL-1beta
CC (By similarity). Has high activity of stimulation of insulin release,
CC which may protect the species from being eaten by predators by causing
CC fatal hypoglycemia (By similarity). Is not cytotoxic to cancer line
CC cells (By similarity). Shows very low hemolysis on horse erythrocytes
CC and moderate hemolysis on mouse erythrocytes (PubMed:28469603) (By
CC similarity). {ECO:0000250|UniProtKB:C0HLE1,
CC ECO:0000269|PubMed:28469603}.
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:28469603}. Target
CC cell membrane.
CC -!- TISSUE SPECIFICITY: Expressed by the skin glands.
CC {ECO:0000305|PubMed:28469603}.
CC -!- PTM: In the synthetic mutant medusin-PT1a [T58K], the Leu-50 has been
CC modified in a D-amino acid. In medusin-PT1a, there is an increase in
CC antimicrobial activity, and an increase in hemolytic activity. It is
CC more potent against S.aureus and gains activity against MRSA,
CC E.faecalis, E.coli, P.aeruginosa and C.albicans. There is an important
CC increase in both biofilm inhibition and biofilm eradication.
CC {ECO:0000269|PubMed:28469603}.
CC -!- MISCELLANEOUS: The primary structure of this peptide is identical to
CC that of Medusin-TR1 (AC C0HLE1). {ECO:0000305}.
CC -!- SIMILARITY: Belongs to the frog skin active peptide (FSAP) family.
CC Medusin subfamily. {ECO:0000305}.
CC -!- WEB RESOURCE: Name=The antimicrobial peptide database;
CC URL="https://wangapd3.com/database/query_output.php?ID=02995";
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; LT591889; SBO46661.1; -; mRNA.
DR AlphaFoldDB; A0A1M4BLT1; -.
DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR GO; GO:0042742; P:defense response to bacterium; IEA:UniProtKB-KW.
DR GO; GO:0050832; P:defense response to fungus; IEA:UniProtKB-KW.
DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR GO; GO:0031640; P:killing of cells of another organism; IEA:UniProtKB-KW.
DR InterPro; IPR004275; Frog_antimicrobial_propeptide.
DR Pfam; PF03032; FSAP_sig_propep; 1.
PE 1: Evidence at protein level;
KW Amidation; Amphibian defense peptide; Antibiotic; Antimicrobial;
KW Cleavage on pair of basic residues; Direct protein sequencing; Fungicide;
KW Immunity; Innate immunity; Membrane; Secreted; Signal;
KW Target cell membrane; Target membrane.
FT SIGNAL 1..22
FT /evidence="ECO:0000255"
FT PROPEP 23..48
FT /evidence="ECO:0000305|PubMed:28469603"
FT /id="PRO_0000449998"
FT PEPTIDE 49..66
FT /note="Medusin-PT"
FT /evidence="ECO:0000269|PubMed:28469603"
FT /id="PRO_5012815711"
FT REGION 25..46
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOD_RES 66
FT /note="Leucine amide"
FT /evidence="ECO:0000269|PubMed:28469603"
FT MUTAGEN 54
FT /note="P->K: In medusin-PT2; increase in antimicrobial
FT activity against Gram-positive bacteria and fungi, and
FT increase in hemolytic activity (is more potent against
FT S.aureus and gains activity against MRSA, E.faecalis, and
FT C.albicans. No change against E.coli and P.aeruginosa.
FT Important increase in biofilm inhibition and small increase
FT in biofilm eradication)."
FT MUTAGEN 58
FT /note="T->K: In medusin-PT1; increase in antimicrobial
FT activity, and increase in hemolytic activity (is more
FT potent against S.aureus and gains activity against MRSA,
FT E.faecalis, E.coli and C.albicans. No change against
FT P.aeruginosa. Important increase in both biofilm inhibition
FT and biofilm eradication). In medusin-PT1a; increase in
FT antimicrobial activity, and increase in hemolytic activity
FT (is more potent against S.aureus and gains activity against
FT MRSA, E.faecalis, E.coli, P.aeruginosa and C.albicans.
FT Important increase in both biofilm inhibition and biofilm
FT eradication)."
SQ SEQUENCE 67 AA; 7696 MW; D781C3379F53B0DF CRC64;
MAFLKKSLFL VFFLGFVSLS ICEEEKRETD EKENEQEDDR EERSEEKRLL GMIPVAITAI
SALSKLG
